QM · rank #3 · 2026-10-26
CDNA
NASDAQ · $3.58B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +326.52% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +29.5% |
| Profit margin Net profit margin, trailing 12 months. | +24.2% |
| Market cap (USD) Size filter: > $500M required. | $3.58B |
| Anchor (recent) Close on 2026-09-25 | $63.68 |
| Anchor (far) Close on 2025-09-26 | $14.93 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
CareDx provides non-invasive transplant rejection surveillance assays (AlloSure/AlloMap) and specialty-oncology molecular residual disease testing (NavDx) for HPV-related head and neck cancers.
Rationale
The high ROE (29.5%) and strong profit margin (24.2%) are reinforced by 52% year-over-year Q2 revenue growth, positive operating cash flow, and raised FY2026 revenue guidance of $490–$500 million.
Material risks
- 1Execution and commercial integration risks for the newly acquired NavDx assay across Epic clinical workflows, revenue-cycle billing, and claims processing.
- 2Heavy dependence on Medicare coverage and payer reimbursement policies for transplant and oncology testing without contracted order backlog or single-source supplier protection.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.